CYP3A4 and fungal infectious disease: Prolonged myelosuppression has been repeatedly reported in clinical trials [1, 5, 8, 35] and real-life series [36–41] as the most frequent adverse event during treatment, and thus, prophylactic measures such as the use of azoles to prevent fungal infection, which requires venetoclax dose adjustment due to CYP3A cytochrome interaction [42–44] or blood transfusions have been adopted in most of the treating institutions (Fig. 4).